Evidence map›Paper›PMID 39159293›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2024

Ginsenoside Rg3 Restores Mitochondrial Cardiolipin Homeostasis via GRB2 to Prevent Parkinson's Disease.

Li-Feng-Rong Qi, Shuai Liu, Qiuyuan Fang, Cheng Qian, Chao Peng, Yuci Liu, Peng Yang, Ping Wu, Ling Shan, Qinghua Cui and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Discovery of TDP-43 aggregation inhibitorsbioRxiv : the preprint server for biology · 2026
    Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Li-Feng-Rong QiState Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, Jiangsu, 210009, China.
Shuai LiuState Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, Jiangsu, 210009, China.
Qiuyuan FangDepartment of Biophysics and Department of Neurosurgery of the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, 310058, China.
Cheng QianState Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, Jiangsu, 210009, China.
Chao PengNational Facility for Protein Science in Shanghai, Zhangjiang Lab, Shanghai Advanced Research Institute, Chinese Academy of Science, Shanghai, 201210, China.
Yuci LiuState Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, Jiangsu, 210009, China.
Peng YangState Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, Jiangsu, 210009, China.
Ping WuNational Facility for Protein Science in Shanghai, Zhangjiang Lab, Shanghai Advanced Research Institute, Chinese Academy of Science, Shanghai, 201210, China.
Ling ShanDept. Neuropsychiatric Disorders, Netherlands Institute for Neuroscience, An Institute of the Royal Netherlands Academy of Arts and Sciences, Meibergdreef 47, Amsterdam, 1105BA, the Netherlands.
Qinghua CuiDepartment of Biomedical Informatics, School of Basic Medical Sciences, Key Laboratory of Molecular Cardiovascular Sciences of the Ministry of Education, Center for Non-Coding RNA Medicine, Peking University Health Science Center Beijing, Beijing, 100191, China.
Qian HuaSchool of Life Sciences, Beijing University of Chinese Medicine, Beijing, 100029, China.
Sen YangLife Sciences Institute, Zhejiang University, Hangzhou, 310058, China.
Cunqi YeLife Sciences Institute, Zhejiang University, Hangzhou, 310058, China.
Wei YangDepartment of Pharmacy, The Fourth Affiliated Hospital, Center for Innovative Traditional Chinese Medicine Target and New Drug Research, International Institutes of Medicine, Zhejiang University School of Medicine, Yiwu, Zhejiang, 322000, China.
Ping LiState Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, Jiangsu, 210009, China.
Xiaojun XuState Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, Jiangsu, 210009, China.ORCID 0000-0003-4379-8748

Funding

National Key R&D Program of China 2023YFA1801100National Natural Science Foundation of China 81973500National Natural Science Foundation of China 82304745Project Program of State Key Laboratory of Natural Medicines, China Pharmaceutical University SKLNMZZCX201820
6 · The paper itself

Abstract

Regulating cardiolipin to maintain mitochondrial homeostasis is a promising strategy for addressing Parkinson's disease (PD). Through a comprehensive screening and validation process involving multiple models, ginsenoside Rg3 (Rg3) as a compound capable of enhancing cardiolipin levels is identified. This augmentation in cardiolipin levels fosters mitochondrial homeostasis by bolstering mitochondrial unfolded protein response, promoting mitophagy, and enhancing mitochondrial oxidative phosphorylation. Consequently, this cascade enhances the survival of tyrosine hydroxylase positive (TH

Indexed as

CardiolipinsDisease Models, AnimalGinsenosidesGRB2 Adaptor ProteinHomeostasisMitochondriaParkinson DiseaseAnimalsHumansMaleMiceMice, Inbred C57BLCardiolipinsginsenoside Rg3GinsenosidesGRB2 Adaptor ProteinGrb2 protein, mousecardiolipinCRLS1EVI1GRB2TRKA

Identifiers

PMID39159293
PMCPMC11497058

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.